Kurtzberg J, Friedman H S, Kinney T R, Chaffee S, Falletta J M
Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710.
Am J Med. 1987 Oct 23;83(4A):30-3. doi: 10.1016/0002-9343(87)90548-1.
Two pediatric patients with severe aplastic anemia, elevated antiplatelet antibody levels, refractoriness to human lymphocyte antigen-matched platelet transfusions, and sustained bleeding problems were treated with intravenous immunoglobulin (IVIG), pH 4.25, for three to over nine months. Improved responses to platelet infusions and improved hemostasis were demonstrated in both patients. A review of the published literature analyzing the role of IVIG in the treatment of platelet alloimmunization is presented.
两名患有严重再生障碍性贫血、抗血小板抗体水平升高、对人类淋巴细胞抗原匹配的血小板输注无效且持续存在出血问题的儿科患者，接受了pH值为4.25的静脉注射免疫球蛋白（IVIG）治疗，疗程为三至九个多月。两名患者均表现出对血小板输注的反应改善以及止血情况改善。本文对已发表的分析IVIG在血小板同种免疫治疗中作用的文献进行了综述。
